Tyra Biosciences, Inc.: management transactions · United States · SEC (Form 4)

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is a U.S.-listed clinical-stage biotechnology company trading on the Nasdaq Global Select Market under the ticker TYRA. Headquartered in Carlsbad, California, United States, the company was incorporated in 2018 and has built its story around precision medicine with a particular focus on FGFR (fibroblast growth factor receptor) biology. For investors in France, Belgium, and Switzerland, TYRA fits the profile of a development-stage biotech: limited or no commercial revenue today, with valuation driven primarily by pipeline quality, clinical execution, and the probability of regulatory success. Tyra’s core strategic asset is its proprietary SNÅP discovery platform, an internal drug-design engine intended to generate highly selective and tolerable molecules through iterative optimization. The company’s lead candidate is dabogratinib, an oral and FGFR3-selective inhibitor. This asset sits at the center of Tyra’s development strategy and is being advanced across multiple phase 2 programs. The current clinical roadmap includes studies in pediatric achondroplasia, intermediate-risk non-muscle invasive bladder cancer, and low-grade upper tract urothelial carcinoma. That mix is notable because it ties together oncology and genetically defined diseases through a common biological target, allowing Tyra to potentially build a broader franchise from a single mechanistic thesis. From a competitive standpoint, Tyra operates in a crowded and scientifically demanding field. It competes indirectly with larger oncology-focused biopharma groups and with other companies pursuing FGFR biology or adjacent targeted therapy approaches. Tyra’s potential differentiation lies in the combination of oral dosing, FGFR3 selectivity, and a design philosophy intended to balance potency, safety, and convenience. However, as with most clinical-stage biotech companies, the investment case remains highly binary. Key risks include trial failure, safety limitations, slower-than-expected enrollment, regulatory delays, and the possibility that early clinical signals do not translate into durable efficacy or eventual approval. Geographically, Tyra’s operations are primarily U.S.-based, with its headquarters in California and its clinical and regulatory activities centered on the United States. Recent company updates in 2025 and 2026 have emphasized continued progress across the dabogratinib program, including advancement of phase 2 trials and the expected sequence of interim data readouts in 2026 and 2027. The company also strengthened its balance sheet through at-the-market equity issuance, improving cash visibility and supporting ongoing development spending. In short, TYRA remains a speculative but focused biotechnology story, with a single lead asset, a proprietary discovery platform, and several near-term clinical catalysts that could materially shape investor sentiment.